KIDNEY INJURY DURING TREATMENT WITH AFLIBERCEPT VERSUS RANIBIZUMAB: A Population-Based Study.

چکیده

Systemically administered anticancer vascular endothelial growth factor inhibiting therapies can cause severe kidney injury. Intravitreal aflibercept has a greater impact on renal vascular endothelial growth factor levels than ranibizumab. We compared the risk of kidney injury among patients…

متن کامل چکیده در سایت ناشر در دسترس است.

موضوعات مرتبط

• درمان های ضد VEGF
• شبکیه